- Home
- ACIC vs VNDA Comparison
ACIC vs VNDA Comparison
Compare ACIC & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIC | VNDA |
|---|---|---|
| Founded | 1999 | 2002 |
| Country | United States | United States |
| Employees | 68 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 538.1M | 474.0M |
| IPO Year | 2007 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ACIC | VNDA |
|---|---|---|
| Price | $11.37 | $7.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $14.90 |
| AVG Volume (30 Days) | 244.0K | ★ 3.8M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.78% | N/A |
| EPS Growth | ★ 39.61 | N/A |
| EPS | ★ 2.15 | N/A |
| Revenue | ★ $335,439,000.00 | $216,105,000.00 |
| Revenue This Year | N/A | $21.35 |
| Revenue Next Year | $1.00 | $37.40 |
| P/E Ratio | $5.15 | ★ N/A |
| Revenue Growth | ★ 13.07 | 8.72 |
| 52 Week Low | $9.97 | $3.81 |
| 52 Week High | $13.06 | $9.91 |
Technical Indicators
Market Signals| Indicator | ACIC | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 52.35 | 38.72 |
| Support Level | $10.97 | $4.36 |
| Resistance Level | $11.85 | $8.29 |
| Average True Range (ATR) | 0.27 | 0.58 |
| MACD | -0.02 | -0.21 |
| Stochastic Oscillator | 54.23 | 8.17 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.